Genetic analysis for drug resistance in urological cancer by whole exome sequencing using xenograft model

2014 Fiscal Year Final Research Report

• Project/Area Number: 24390367
• Research Category: Grant-in-Aid for Scientific Research (B)
• Allocation Type: Partial Multi-year Fund
• Section: 一般
• Research Field: Urology
• Research Institution: Kyoto University
• Principal Investigator: KAMBA Tomomi 京都大学, 医学(系)研究科(研究院), 准教授 (20402836)
• Co-Investigator(Kenkyū-buntansha): YAMASAKI Toshinari 京都大学, 医学研究科, 助教 (00607749) ; INOUE Takahiro 京都大学, 医学研究科, 講師 (80511881) ; OGAWA Osamu 京都大学, 医学研究科, 教授 (90260611)
• Project Period (FY): 2012-04-01 – 2015-03-31
• Keywords: 腎癌 / 前立腺癌 / ｍTOR / 全エクソンシークエンス / 薬剤耐性

Outline of Final Research Achievements

In this study, we aim to elucidate potential resistance mechanisms in urological cancer in vivo model by exome sequencing. We have generated several cohort of patient-derived primary xenograft model, and some of which develop complete resistance to temsirolimus or sunitinib with continuous drug exposure. We performed whole exome sequencing. Comparison of resistant and control data identified common Non-synonymous single nucleotide variants (SNVs) among resistant tumor that were absent in control tumor.　Further studies to explore whether these variants arise in urological cancer are expected to reveal the clinical relevance of genetic alterations identified in these model system.

Free Research Field

泌尿器科癌